• Earlier this week, TJ Biopharma announced a definitive agreement under which Biogen will acquire its exclusive Greater China rights to felzartamab for up to US$850 million, giving Biogen worldwide control of the Phase 3 anti-CD38 antibody and responsibility for future development, manufacturing, and commercialization in the region.
• This deal consolidates felzartamab under one owner across multiple immune-mediated diseases and multiple myeloma in China, tightening the link between Biogen’s late-stage pipeline progress and its long-term growth story.
• Next, we’ll examine how gaining full global control of felzartamab could reshape Biogen’s investment narrative and risk-reward profile.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Biogen Investment Narrative Recap

To own Biogen today, you need to believe the company can shift from legacy MS dependence toward a more diversified set of neurology and immunology drugs, with late stage assets driving the next leg of the story. The felzartamab China deal strengthens that pipeline link, but it does not change that the key near term swing factor remains upcoming data for BIIB080 and litifilimab, while execution risk around a handful of newer launches still looms largest.

Against this backdrop, UBS’s recent upgrade of Biogen, citing a concentrated window of late stage catalysts including BIIB080, litifilimab and felzartamab, is particularly relevant. Felzartamab’s global consolidation ties Biogen’s China opportunity more directly to those same readouts, potentially sharpening how investors connect trial outcomes across neurology and immunology when they think about the stock’s overall catalyst path.

Yet, even with a stronger felzartamab story, investors should be aware that concentrated reliance on a few launches still leaves Biogen exposed if...

Biogen's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2028. This assumes revenue will decline by 2.1% per year and requires an earnings increase of about $0.6 billion from $1.5 billion today.

Uncover how Biogen's forecasts yield a $205.67 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view that highlights pipeline breadth and the felzartamab deal, the most bearish analysts were assuming revenues could fall toward about US$8.6 billion and still only support earnings near US$1.9 billion by 2029, so this new China acquisition may ultimately push some of those more pessimistic expectations to evolve in very different ways.

Explore 7 other fair value estimates on Biogen - why the stock might be worth 18% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 56 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.